sgn-b6a
mAbexperimentalADC
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started May 30, 2020 (NCT04389632)
Timeline
Indications
Studied for
- Breast Neoplasms · Phase 1
- Carcinoma, Non-Small-Cell Lung · Phase 3
- Carcinoma, Squamous Cell · Phase 1
- Esophageal Neoplasms · Phase 1
- Esophageal Squamous Cell Carcinoma · Phase 1
- Ovarian Neoplasms · Phase 1
- Pancreatic Neoplasms · Phase 1
- Squamous Cell Carcinoma of Head and Neck · Phase 1
- Stomach Neoplasms · Phase 1
- Urinary Bladder Neoplasms · Phase 1
- Uterine Cervical Neoplasms · Phase 1
Mechanism of action
- Integrin alpha-V/beta-6INHIBITOR
Integrin alpha-V/beta-6 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
- Payload
- MMAE
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06012435 | Phase 3 | Nov 30, 2023 | Seattle Genetics |
| NCT04389632 | Phase 1 | May 30, 2020 | Seattle Genetics |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Seattle Genetics | For profit | 2 | 2 | 2 | 2020 |
1 organizations
Page 1 / 1